169例BCLCB期肝细胞癌切除术预后因素分析

目的探讨BCLCB期肝细胞癌（hepatocellular carcinoma,HCC）患者手术切除预后的影响因素。方法收集2003年3月至2007年9月169例BCLCB期HCC手术切除患者的临床病理资料,采用Kaplan-Meier法计算术后累积生存率,以Log-rank显著性检验初步筛选出可能影响HCC预后的相关因素,应用Cox回归分析进一步明确影响预后的独立因素。结果 BCLCB期HCC患者术后1、3、5年累积生存率分别为76.3%、46.0%、38.8%。单因素分析表明术前谷丙转氨酶（ALT）、肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗影响HCC术后累计生存率（P〈0.05）。多因素分析表明肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗是影响HCC术后生存率的独立因素（P〈0.05）。结论手术切除是BCLCB期HCC患者有效的治疗手段,肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗是其预后的独立影响因素。     

169例BCLCB期肝细胞癌切除术预后因素分析

目的探讨BCLCB期肝细胞癌(hepatocellular carcinoma,HCC)患者手术切除预后的影响因素。方法收集2003年3月至2007年9月169例BCLCB期HCC手术切除患者的临床病理资料,采用Kaplan-Meier法计算术后累积生存率,以Log-rank显著性检验初步筛选出可能影响HCC预后的相关因素,应用Cox回归分析进一步明确影响预后的独立因素。结果 BCLCB期HCC患者术后1、3、5年累积生存率分别为76.3%、46.0%、38.8%。单因素分析表明术前谷丙转氨酶(ALT)、肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗影响HCC术后累计生存率(P<0.05)。多因素分析表明肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗是影响HCC术后生存率的独立因素(P<0.05)。结论手术切除是BCLCB期HCC患者有效的治疗手段,肿瘤包膜、肿瘤数目、肝硬化和术后辅助治疗是其预后的独立影响因素。     

复发性肝癌再切除术患者预后因素分析

目的：探讨影响复发性肝癌再切除术的预后因素。方法：回顾性分析41例行再切除术复发性肝癌患者的临床病理资料及随访记录,采用Kaplan-Meier 和Log-rank 对数秩检验对23个临床病理因素进行单因素分析,然后引入Cox 比例风险模型进行多因素分析。另外,对各次术中失血量及手术时间采用单因素方差分析进行比较。结果：再次手术后患者1、3、5 年生存率分别为68% 、36% 、35% ,无瘤生存率分别为39% 、22% 、7% 。影响生存期的独立预后因素为：第1 次手术时门静脉癌栓形成、第1 次手术时肝硬化结节直径大小、第2 次手术切缘距离、第2 次手术后辅助治疗。未得出影响无瘤生存期的独立预后因素。各次术中失血量及手术时间无显著性差异。结论：第1 次手术中合并门静脉癌栓或硬化结节直径较大的患者,行再切除术预后差。第2 次手术中肝切缘距离>1cm或者术后辅以其他综合治疗可以改善患者预后。     

肝细胞癌手术切缘对患者术后复发与生存的影响

目的 比较不同的手术切缘对肝癌患者术后复发及生存的影响,为肝癌患者手术中选择合理切缘提供参考。方法 将152例初治的可手术切除肝癌患者随机分为两组,分别按以下标准手术：74例宽切缘组患者按门静脉血流方向远端距肿瘤边缘2cm,近端距肿瘤边缘1cm完整切除;78例窄切缘组患者切除范围距离肿瘤〈1cm,切缘无癌残留。应用Kaplan-Meier法进行生存分析,用Log rank检验分别比较两组的无瘤生存期和总生存期。结果 宽切缘组患者平均无瘤生存期为35．5个月,平均总生存期为42．0个月;窄切缘组患者平均无瘤生存期为28．8个月,平均总生存期为37．5个月,两组无瘤生存期（t=6．01,P=0．0142）和总生存期（t=6．23,P=0．0125）比较,差异均有统计学意义。结论 按门静脉血流方向远端距肿瘤2cm,近端距肿瘤1cm切除为标准的手术范围可较合理地延长肝癌患者术后无瘤生存期和总生存期。     

肝内胆管细胞癌患者的预后影响因素分析

目的 分析影响肝内胆管细胞癌(ICC)患者预后的相关临床病理因素,并对ICC的外科治疗方式进行探讨.方法 回顾性分析43例经病理证实为ICC患者的临床病理资料.43例[CC患者中,40例行肝切除术,2例在剖腹探查时行无水酒精注射,1例仅行剖腹探查.采用单因素和Cox回归模型对可能影响ICC患者术后生存的因素进行分析.结果 全组43例患者的1、3和5年生存率分别为64.4%、30.9%和25.8%.40例行肝切除患者的术后1、3和5年生存率分别为74.7%、33.3%和27.8%.单因素分析结果显示,肿瘤直径、有无淋巴结转移、癌胚抗原(CEA)水平和TNM分期与ICC患者的术后生存显著相关(均P＜0.05).Cox多因素分析结果显示,肿瘤直径和有无淋巴结转移是影响ICC患者术后生存的独立因素(均P＜0.05).结论 肿瘤直径和有无淋巴结转移是影响ICC患者术后生存的独立因素,CEA水平和TNM分期是影响ICC患者术后生存的重要因素.对ICC患者应选择行根治性肝切除术.     

48例复发性肝细胞癌再次切除术后的疗效及预后因素分析

目的:分析复发性肝细胞癌行再次切除术后的疗效和影响预后的因素。方法:回顾性分析中山大学附属肿瘤医院和江西省人民医院1995年7 月至2003年7 月48例复发性肝细胞癌患者行再次肝切除术的临床病理资料,包括患者性别、年龄、原发肿瘤和复发肿瘤的病理学特征、再次肝切除术前全身状况、复发的出现时间及生存期等,根据随访结果计算总生存率和无瘤生存率,并作单因素及多因素分析。结果:48例患者再次切除术后中位生存时间36.3 个月,1、3、5 年累积生存率分别为81.3% 、45.8% 、27.1% ,1、3、5 年无瘤生存率分别为70.8% 、25.0% 、16.7% 。单因素分析结果显示:原发肿瘤TNM分期、原发肿瘤伴血管侵犯、复发间隔时间、复发肿瘤大小、复发肿瘤TNM分期、复发肿瘤伴血管侵犯影响再切除术后累积生存率;复发间隔时间、原发肿瘤TNM分期、复发肿瘤大小、复发肿瘤有无血管侵犯、复发肿瘤病理分级和AFP 水平影响再切除术后无瘤生存率。多因素分析显示:复发间隔时间、复发肿瘤TNM分期是影响复发性肝癌再切除术后累积生存的独立危险因素;复发间隔时间、复发肿瘤大小是影响其无瘤生存的独立危险因素。结论:肝内复发间隔时间短（≤24个月）、复发肿瘤直径>5cm、复发肿瘤TNM分期越晚,提示再次切除术后预后不良。      

中晚期肝细胞癌预后影响因素分析

目的研究中晚期肝细胞癌(HCC)患者的预后相关因素,建立具有临床实用性的预后模型.方法根据166例HCC患者临床及随访资料,采用Kaplan-Meier和Cox回归模型方法,分析HCC患者的预后影响因素,并建立预后指数(PI)模型.结果单因素分析显示Child-Pugh分级、肝外转移、腹水、治疗、胆红素、血清钠、碱性磷酸酶、γ-谷氨酰转肽酶、肿瘤形态和大小、临床分期和门静脉癌栓与HCC患者生存率有关.多因素分析表明,肿瘤形态(P=0.001)、肿瘤大小(P=0.002)、甲胎蛋白(P=0.014)、血清钠(P=0.011)和Child-Pugh分级(P=0.001)是独立的预后影响因素.预后指数(PI)定义为回归方程:PI=ey,y=0.585(肿瘤形态-2.0542) 0.747(肿瘤大小-1.879) 0.477(AFP-1.4157)-0.570(血清钠-1.6933) 0.786(Child-Pugh分级-1.7590).PI＜1和≥1患者的中位生存期分别为10.2个月和1.8个月(P＜0.01).结论肿瘤形态、肿瘤大小、甲胎蛋白、血清钠和Child-Pugh分级是中晚期HCC患者独立的预后影响因素,根据独立预后因素建立的预后指数模型可帮助临床预测中晚期HCC患者的预后.     

肝细胞癌患者根治性切除术后的生存影响因素分析

目的 探讨肝细胞癌(hepatocellular carcinoma,HCC)根治性切除术后总生存期(overall survival,OS)的影响因素.方法 回顾性收集于山东第一医科大学第二附属医院及山东大学第二医院行根治性切除术的1744例HCC患者的临床资料,采用Cox回归分析影响OS的因素,利用R语言survm...     

肝细胞癌根治性切除术后复发的危险因素

自１９７５年至１９９１年，３０８例肝细胞癌患者行根治性切除术，术后１，２，３，４，５和１０年的复发率分别为１２．７％，２８．７％，４１．２％，４７．４％，５４．１％和６４．４％。到１９９２年３月，共有１３４例复发。复发的危险因素经Ｃｏｘ模型分析，单因素分析发现高的ｒ－ＧＴ，发现途径，严重的肝硬化，门静脉癌栓，局部切除术为复发的危险因素。经多因素分析后发现，只有高的ｒ－ＧＴ，严重的肝硬化，局部切除术与复发有统计学意义。作者认为严重的肝硬化妨碍了肝切除的范围，局部切除术后的综合治疗可减少复发     

30例肝癌术后肝内复发灶的再切除治疗

目的探讨原发性肝癌术后复发的治疗措施,旨在提高肝癌术后的远期疗效。方法回顾性分析我院自1990年1月至2004年12月手术切除的30例肝癌术后复发的再切除治疗资料。结果30例肝癌术后复发再切除34例次,二次手术30例,三次手术4例,其中包括3例肝移植;第一次手术与第二次手术平均间隔时间为(40.8±13.1)个月,第二次手术与第三次手术平均间隔时间为(23.0±19.9)个月(P<0.05);30例原发肿瘤平均最大直径为(6.5±2.1)cm,复发病灶平均最大直径为(3.8±1.2)cm(P<0.05)。结论再切除治疗复发性肝细胞癌是延长肝癌病人生存时间的有效手段;肝移植治疗复发性肝癌仍在探索中。     

Radiation therapy for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma

Background. The intrahepatic recurrence rate after curative hepatectomy for hepatocellular carcinoma (HCC) is high, and management of recurrence is thus important for long-term survival. The use of radiation therapy has been relatively uncommon in the treatment of recurrent HCC.Methods. Eight patients underwent radiation therapy for recurrent HCC 12–98 months after hepatectomy. Five of them were treated with protons (250MeV; 68.8–84.5Gy), and three were treated with X-rays (6MV; 60 or 70Gy). One patient received radiation therapy twice for another lesion with a 79-month interval. The target tumors were 1.2–4.5cm. All patients also underwent transcatheter arterial embolization or other regional therapy.Results. Although transient ascites was found in three patients after radiation therapy, no patient died as a result of the irradiation. Seven patients died 9 months to 4 years (median 1 year 6 months) after radiation therapy. Re-recurrence was observed in the irradiated liver in two patients (local control 78%). Four patients died of lung metastasis after radiation therapy. The median survival time was 3 years 3 months (range 1 year 1 month to 8 years 6 months) after recurrence.Conclusion. Multimodality therapy is necessary for the management of recurrence. Radiation therapy could be beneficial when other therapies present some difficulty regarding application or are performed incompletely. It must be emphasized that radiation therapy should be considered in addition to other regional therapies for the treatment of recurrent or re-recurrent HCC, and that radiation therapy can be repeated in selected patients.     

经皮射频消融术治疗外科切除术后复发性肝细胞癌疗效分析

背景与目的：大部分复发性的肝癌结节的直径小于3 cm,且射频消融(radiofrequency ablation,RFA)治疗直径小于3 cm的肿瘤结节,其疗效已受到广泛认可。探讨RFA对手术切除术后复发性肝细胞癌(hepatocellular carcinoma,HCC)的临床疗效与安全性。方法：回顾性分析61例手术切除后复发性HCC患者在经动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)结合RFA的治疗下的1、3、5年总生存(overall survival,OS)率和无进展生存(progression-free survival,PFS)率,并发症发生率,死亡率,完全消融率以及影响患者生存率的独立风险因子。结果：完全消融率为93.4%(57/61),不完全消融率6.6%(4/61)。1、3、5年生存率分别为96.3%、77.9%和77.9%。1、3、5年PFS率分别为48.6%、20.3%和13.5%。消融术后出现主要并发症的患者1例,为肝包膜下出血;无消融治疗相关的死亡患者;消融后住院时间为4~7 d,中位值为5 d。影响OS的独立风险因子为患者HBsAg阳性(P=0.044,HR=7.496,95%CI：1.057~53.152)。结论：RFA治疗手术切除术后复发的HCC安全、有效,能够有效提高切除术后复发性HCC患者的生存率,对改善HCC患者的预后具有重要意义。     

Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva

Objective

To analyze the prognostic factors related to the recurrence rate of vulvar cancer.

Methods

Retrospective study of 87 patients diagnosed of vulvar squamous cell carcinoma diagnosed at a tertiary hospital in Madrid between January 2000 and December 2010.

Results

The pathological mean tumor size was 35.1±22.8 mm, with stromal invasion of 7.7±6.6 mm. The mean free margin after surgery was 16.8±10.5 mm. Among all patients, 31 (35.6%) presented local recurrence (mean time 10 months; range, 1 to 114 months) and 7 (8%) had distant metastases (mean time, 5 months; range, 1 to 114 months). We found significant differences in the mean tumor size between patients who presented a relapse and those who did not (37.6±21.3 mm vs. 28.9±12.1 mm; p=0.05). Patients with free margins equal or less than 8 mm presented a relapse rate of 52.6% vs. 43.5% of those with free margin greater than 8 mm (p=0.50). However, with a cut-off of 15 mm, we observed a local recurrence rate of 55.6% vs. 34.5%, respectively (p=0.09). When the stromal invasion cut-off was >4 mm, local recurrence rate increased up to 52.9% compared to 37.5% when the stromal invasion was ≤4 mm (p=0.20).

Conclusion

Tumor size, pathologic margin distance and stromal invasion seem to be the most important predictors of local vulvar recurrence. We consider the cut-off of 35 mm of tumor size, 15 mm tumor-free surgical margin and stromal invasion >4 mm, high risk predictors of local recurrence rate.     

Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy.

To establish useful predictors of the intrahepatic recurrence of hepatocellular carcinoma (HCC) after partial hepatectomy, retrospective analyses of clinical and pathologic factors were done in 112 of 206 patients treated by partial hepatectomy. The absence or presence of intrahepatic recurrence was confirmed by a follow-up study. Cancer-free survival rates after 1, 2, 3, and 5 years were 54.8%, 36.7%, 32.5%, and 25.6%, respectively. The significant factors affecting recurrence were tumor size, number of tumors, cancer cell infiltration of the fibrous capsule of the tumor, portal involvement, and stage of the tumor, but the grade of anaplasia according to Edmondson-Steiner's classification and the severity of associated liver cirrhosis did not show a correlation with the incidence of recurrence. According to Akaike's Information Criteria (AIC), tumor number is useful for predicting early prognosis, and capsular infiltration is a good indicator of long-term survival. However, portal involvement gives much prognostic information throughout the entire postoperative period.     

INFLUENCE FACTORS TO RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER SURGICAL RESECTION

Duetomanyreasons,therecurrenceofhepatocellularcarcinoma(HCC)aftersurgicalresectioniseasilytakenplace.Thefocusofrecurrencecannotbere-resectedforthegreatpartofthepateints.Thetreatmentoftranscatheterarterialchemoembolization(TAE)wasperformedforthesepatients.Howtodecreasetherecurrencerateandincreasesurvivalrateofthesepatientsisoneofimportantproblems.Thecurrentstudywasestablishedtofindtherelationshipwithprimaryhepatocellularcarcinomaandrecurrencetumors,bysurgicalresectionfindings,pathologicalexa…     

Prognostic effect of steatosis on hepatocellular carcinoma patients after liver resection

Aims

Overweight/obesity is currently a common health issue that may cause many diseases, even malignancies. The influence of steatosis on long-term results of surgical treatment for hepatocellular carcinoma (HCC) is not well known. The aim of this study is to analyze the results of hepatectomy for HCC patients with steatosis.

Methods

The study included 1048 patients who underwent hepatectomy for HCC from 1999 to 2005. The patients were divided into two groups; group A patients without steatosis (n = 693) and group B patients with steatosis (n = 355). The clinicopathological data and long-term survival were analyzed.

Results

Mean tumor size in group B patients was smaller than that in group A patients (4.61 ± 3.40 vs. 5.91 ± 4.36 cm, p < 0.01). Group B patients showed lower tumor differentiation grade, lower vascular invasion rate and better 5-year overall survival compared to group A patients (61.2% vs. 50.1%, p = 0.001). By multivariate analysis, steatosis was found to be associated with well-differentiated, small-sized, and less α-fetoprotein productive tumors. When focusing on the tumors >5 cm in diameter, group B patients had better survival rate than group A patients (p = 0.041). Vascular invasion and steatosis were independent prognostic factors for the overall survival.

Conclusion

HCC in steatotic liver was less aggressive than that in non-steatotic liver. HCC patients with steatosis have better surgical outcomes than those without steatosis. Vascular invasion and steatosis were independent prognostic factors for the overall survival if tumors were >5 cm in diameter.     

RISK FACTORS FOR RECURRENCE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER RADICAL RESECTION

ＲＩＳＫＦＡＣＴＯＲＳＦＯＲＲＥＣＵＲＲＥＮＣＥＩＮＰＡＴＩＥＮＴＳＷＩＴＨＨＥＰＡＴＯＣＥＬＬＵＬＡＲＣＡＲＣＩＮＯＭＡＡＦＴＥＲＲＡＤＩＣＡＬＲＥＳＥＣＴＩＯＮＺｈａｎｇＢｏｈｅｎｇ张博恒ＺｈｏｕＸｉｎｄａ周信达ＹｕＹｅｑｉｎ余业勤ＴａｎｇＺｈａ...